A large Hong Kong-licensed hedge fund manager in the launch of a new, Asia-biased but market neutral hedge fund (involving consultations over, amongst other factors, the fund’s liquidity model, target concentration limits and risk/return profile).

A major non-US sovereign wealth fund in co-financing the clinical development of several potentially groundbreaking, pre-approval/market drugs/devices, including: Bempeg (a potential cure for head and neck cancer); Bardoxolone Methyl (for preventing end-stage renal disease (i.e., kidney failure)); Inclisiran (for treating heart disease using first-of-its-kind siRNA technology); and Medtronic, Inc.’s “Intrepid” transcatheter mitral valve replacement system.

The investment arm of an Asian e-commerce platform on a strategic JV investment in a German partnership designed for investment in sustainable food initiatives (e.g., alternative protein products, clean nutrition, functional food, food waste reduction).

A large Singaporean bank in the development of compliance systems and infrastructure around whether, when and how to deal with US person advisers, investors and intermediaries under covered U.S. laws and regulations.